Request Trial
shutterstock-108126005
Zemler / Shutterstock.com
19 December 2014PharmaTrevor Cook

Marketing authorisation: the right to challenge

Since the EU regime of data exclusivity for pharmaceuticals was amended in late 2005, in large part to reflect Court of Justice of the EU (CJEU) case law in the 1990s and early 2000s, there has been little case law on the interpretation of the new legislation. This situation is now starting to change.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
8 October 2026   Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.
Pharma
MSD’s Keytruda hit by eight-country ban across Europe
8 October 2026   Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026   Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.


Editor's picks

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026

Editor's picks

Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026

More features

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
MSD’s Keytruda hit by eight-country ban across Europe
WATCH: LEO Pharma head of IP rights on doing more with less
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year
Fish & Richardson nets patent litigator to grow European practice
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Takeda sees off UK challenge to Elvanse SPC